Product Comparison


 

No Image

No Image

No Image

No Image

No Image

McKesson # 1177540 1124666 1054035 1177542 1054036
Description Leflunomide 10 mg Tablet Bottle 30 Tablets Orencia® Abatacept / Maltose, Preservative Free 250 mg / 15 mL Injection Single Use Vial 15 mL Leflunomide 10 mg Tablet Bottle 30 Tablets Leflunomide 20 mg Tablet Bottle 30 Tablets Leflunomide 20 mg Tablet Bottle 30 Tablets
Manufacturer # 7074801290600003218713623320061307074801300662332006230
Brand  Orencia┬«   
Manufacturer Lupin PharmaceuticalsBristol-Myers SquibbAlembic PharmaceuticalsLupin PharmaceuticalsAlembic Pharmaceuticals
Invoice LEFLUNOMIDE, TAB 10MG (30/BT)ORRENCIA, VL 250MGLEFLUNOMIDE, TAB 10MG (30/BT) RXLEFLUNOMIDE, TAB 20MG (30/BT)LEFLUNOMIDE, TAB 20MG (30/BT) RX
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Alternate Manufacturer Number 3976305358659115594003622032
Container Type BottleSingle Use VialBottleBottleBottle
Dosage Form TabletInjectionTabletTabletTablet
Generic Drug Code 263066703167032
Generic Drug Name LeflunomideAbatacept / Maltose, Preservative FreeLeflunomideLeflunomideLeflunomide
NDC Number 7074801290600003218713623320061307074801300662332006230
Product Dating McKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 days
Storage Requirements Requires Refrigeration
Strength 10 mg250 mg / 15 mL10 mg20 mg20 mg
Type Film CoatedIntravenousFilm CoatedFilm CoatedFilm Coated
UNSPSC Code 5120250151203801512025015120250151202501
Volume 30 Tablets15 mL30 Tablets30 Tablets30 Tablets
Application Disease-Modifying Antirheumatic AgentDisease-Modifying Antirheumatic AgentDisease-Modifying Antirheumatic AgentDisease-Modifying Antirheumatic AgentDisease-Modifying Antirheumatic Agent
Country of Origin UnknownUnknownUnknownUnknownUnknown
Features and Benefits
  • ORENCIA┬« (abatacept) is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA